Advertisement
Screener

FULCRUM THERAPEUTICS, INC. (FULC) Executive Pay versus Performance: Pay versus Performance

FULCRUM THERAPEUTICS, INC. Pay versus Performance

The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.

  • 2025-12-31: Other NEO average total compensation $1.64M.
  • 2024-12-31: Other NEO average total compensation $2.14M.
  • 2023-12-31: PEO Bryan Stuart; Other NEO average total compensation $2.13M.
  • 2024-12-31: Other NEO average total compensation $2.14M.
Fiscal year endPEOPEO total compensationPEO compensation actually paidOther NEO average total compensationOther NEO average compensation actually paidTotal shareholder returnPeer group total shareholder returnNet incomeCompany-selected measureProxy filed
2025-12-31$1.64M$4.47M$15536.00-$74.88M2026-04-30
2024-12-31$2.14M$610.99K$6456.00-$9.73M2026-04-30
2023-12-31Bryan Stuart$2.13M$1.90M$9272.00-$97.34M2026-04-30
2024-12-31$2.14M$610.99K$6456.00-$9.73M2025-04-30
2023-12-31$2.13M$1.90M$9272.00-$97.34M2025-04-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02